Maysoon Al Adham

Maysoon Al Adham

Auto-generated profile, based on publicly available information

Maysoon Al Adham

College of Medicine, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, 11481 Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Obstetrics and Gynecology International
Verified
Journal Article
Open access
RARenad A. Alshalan
Renad A. Alshalan
RARwan K. Alarfaj
Rwan K. Alarfaj
YAYazeed A. Almojel
Yazeed A. Almojel
YAYara AlHaddad
Yara AlHaddad
RARahaf Alsomali
Rahaf Alsomali
MAMaysoon Al Adham
Maysoon Al Adham
Introduction. The physiological process by which the fetus and placenta are delivered from the uterus and pass through the vaginal canal for delivery is known as labor. Induction of labor involves deliberately initiating labor before it occurs naturally, using medical interventions or techniques to stimulate contractions and initiate the birthing process. Aim. This study aimed to investigate the factors that influence the success of labor induction procedures in Riyadh, Saudi Arabia, from January to April 2023. Subject and Methods. This retrospective chart review was conducted at the National Guard Hospital in Riyadh, Saudi Arabia. Data were collected from the patient chart of those who underwent labor induction from January to April 2023. The collected data were tabulated and cleaned in MS Excel. Final data were transferred to SPSS for subsequent data analysis. Results. Five hundred and thirty‐one pregnant women were analyzed. 52.7% were aged 30 years or below. The most common indication of IOL was post‐dated pregnancy (26.2%). 62% were normal deliveries, indicative of IOL success, while 31.1% were cesarean deliveries, indicative of IOL failure. In univariate analysis, women with lower gravidity (≤3) and who had received Propess were associated with cesarean delivery. In a multivariate regression analysis, women who received Prostin and increased parity were identified as the significant independent predictors of IOL success. Conclusion. IOL’s success was dependent primarily on increasing parity and Prostin administration. However, lower gravidity (≤3) and Propess medication could lead to operative procedures among pregnant women. Hence, it is necessary to carefully assess the condition of pregnant women before directing them to IOL.

17 December 2025 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
NANorah Hussain Alqntash
Norah Hussain Alqntash
YAYara Arfaj
Yara Arfaj
RSRawan Ali Bin Salamah
Rawan Ali Bin Salamah
MSMohammad H. Sindi
Mohammad H. Sindi
HAHissah Alshareef
Hissah Alshareef
MAMaysoon Al Adham
Maysoon Al Adham
Background: Gefitinib is a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), mainly used for non-small cell lung cancer. Because EGFR is also highly expressed in placental tissue, its use has been explored in the treatment of ectopic pregnancy. This review examines the available evidence on the safety and effectiveness of combining gefitinib with methotrexate for the treatment of ectopic pregnancy. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was conducted across PubMed, Web of Science, ProQuest, and Google Scholar for English-language studies published between 2013 and 2023 comparing gefitinib plus methotrexate to methotrexate alone. Study quality was assessed using Joanna Briggs Institute (JBI) tools for quasi-experimental studies and case reports. Meta-analysis was performed using OpenMeta-Analyst with a random-effects model at a 0.05 significance level and 95% confidence intervals (CI). Results: Of 162 identified studies, five met the inclusion criteria, and three were included in the meta-analysis, comprising 526 participants. The pooled analysis revealed no statistically significant difference in complete resolution rates between the combination therapy group (69.3%) and the methotrexate-alone group (75.5%) (relative risks (RR): 1.004, 95% CI: 0.802–1.257; p = 0.973; I2 = 63.96%). Adverse events were generally mild and self-limiting, with rash (60.8%) and diarrhea (46.5%) being the most common. Serious adverse events were rare (<4%) and occurred at similar rates in both groups. Conclusions: These findings suggest that while the combination of gefitinib and methotrexate is safe, it does not significantly enhance treatment outcomes compared to methotrexate alone in managing ectopic pregnancy. Registration: The study has been registered on https://www.crd.york.ac.uk/prospero/ (registration number: CRD42024500567; registration link: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024500567).